Tachycardia-induced cardiomyopathy: Mechanisms of heart failure and clinical implications

Journal of Cardiovascular Medicine

Volumn 8, Issue 3, 2007, Pages 138-143

  Calò, Leonardo ^a,c   De Ruvo, Ermenegildo ^a   Sette, Antonella ^a   Sciarra, Luigi ^b   Scioli, Roberto ^a   Sebastiani, Francesco ^a   Topai, Marco ^a   Iulianella, Renzo ^a   Navone, Giovanna ^a   Lioy, Ernesto ^a   Gaita, Fiorenzo ^b  

^a ASL Roma B   (Italy)

^b Civil Hospital   (Italy)

^c Policlinico Casilino   (Italy)

Author keywords

Cardiac dysrhythmias; Congestive heart failure; Electrophysiology

Indexed keywords

AMIODARONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; PROBUCOL; SELEGILINE;

CONGESTIVE CARDIOMYOPATHY; FETAL TACHYDYSRHYTHMIA; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TACHYCARDIA INDUCED CARDIOMYOPATHY;

ANIMALS; ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; HEART FAILURE, CONGESTIVE; HUMANS; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR; VENTRICULAR DYSFUNCTION;

EID: 33847139750     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000260841.30415.62     Document Type: Review

References (57)

1. Coleman HN III, Taylor RR, Pool PE, Whipple GH, Covell JW, Ross J Jr, Braunwald E. Congestive heart failure following chronic tachycardia. Am Heart J 1971; 81:790-798.
2. Cruz FE, Cheriex EC, Smeets JL, Atie J, Peres AK, Penn OC, et al. Reversibility of tachycardia induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 1990; 16:739-744.
3. Lemery R, Brugada P, Cheriex E, Wellens HJ. Reversibility of a tachycardia-induced LV dysfunction after closed chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol 1987; 60:1406-1408.
4. Rakovec P, Lajovic J, Dolenc M. Reversible congestive cardiomyopathy due to chronic ventricular tachycardia. PACE 1989; 12:542-545.
5. Fyfe DA, Gillette PC, Crawford FA Jr, Kline CH. Resolution of dilated cardiomyopathy after surgical ablation of ventricular tachycardia in a child. J Am Coll Cardiol 1987; 9:231-234.
6. Shinbane JS, Wood MA, Jensen DN, Ellebongen KA, Fitzpatrick AP, Sheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical study. J Am Coll Cardiol 1997; 29:709-715.
7. Fenelon G, Wijins W, Andries E, Brugada P. Tachycardiomyopathy: mechanism and clinical implications. PACE 1996; 19:95-106.
8. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995; 92:2306-2317.
9. Howard RJ, Stopps TP, Moe GW, Gotlieb A, Armstrong PW. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol 1988; 66:1505-1512.
10. Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, et al. Probucol attenuates left ventricular dysfunction and remodelling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 2002; 106:362-367.
11. Qin F, Shite J, Mao W, Liang CS. Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur J Pharmacol 2003; 461:149-158.
12. Aguinaga L, Primo J, Anguera I, Mont L, Valentino M, Brugada P, Brugada J. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. PACE 1998; 21:2073-2078.
13. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570-1573.
14. Rabbani LE, Wang PJ, Couper GL, Friedman PL. Time course of improvement in ventricular function after ablation of incessant automatic atrial tachycardia. Am Heart J 1991; 121:816-819.
15. Van Gelder IC, Crijns HJ, Blanksma PK, Landsman ML, Posma JL, Van Den Berg MP, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72:560-566.
16. Noe P, Van Driel V, Wittkampf F, Sreeram N. Rapid recovery of cardiac function after catheter ablation of persistent junctional reciprocating tachycardia in children. PACE 2002; 25:191-194.
17. Fishberger SB, Colan SD, Saul IP, Mayer JE, Walsh EP. Myocardial mechanics before and after ablation of chronic tachycardia. PACE 1996; 19:42-49.
18. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998; 32:205-210.
19. Calo L, Sciarra L, Scioli R, Lamberti F, Loricchio ML, Pandozi C, Santini M. Recovery of cardiac function after ablation of atrial tachycardia arising from the tricuspid annulus. Ital Heart J 2005; 6:652-657.
20. Corey WA, Markel ML, Hoit BD, Walsh RA. Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J 1993; 126:1469-1473.
21. Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 1998; 73:430-433.
22. Chugg SS, Shen WK, Luria DM, Smith HC. First evidence of premature complex-induced cardiomyopathy: a potentially reversible cause of heart failure. J Cardiovasc Electrophysiol 2000; 11:328-329.
23. Redfeam DP, Hill JD, Keal R, Toff WD, Stafford PJ. Left ventricular dysfunction resulting from frequent unifocal ventricular ectopics with resolution following radiofrequency ablation. Europace 2003; 5:247-250.
24. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988; 85:242-244.
25. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563-570.
26. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. Outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42:185-197.
27. Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, et al. Atrial electroanatomical remodelling after circumferential radiofrequency pulmonary vein ablation. Circulation 2001; 104:2539-2544.
28. Nair M, Shah P, Batra R, Kumar M, Mohan J, Kaul U, Arora R. Chronic atrial fibrillation in patients with rheumatic heart disease. Circulation 2001; 104:802-809.
29. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-666.
30. Calo L, Lamberti F, Loricchio ML, Castro A, Shpun S, Boggi A, et al. Long-term follow-up of right atrial ablation in patients with atrial fibrillation: efficacy and impact of a hybrid approach on quality of life. J Cardiovasc Electrophysiol 2004; 15:1-7.
31. Gallagher JJ, Sealy WC. The permanent form of junctional reciprocating tachycardia: further elucidation of the underlying mechanism. Eur J Cardiol 1978; 8:413-430.
32. Coumel P, Cabrol C, Fabiato A, Gourgon R, Slama R. Tachycardie permanente par rythme reciproque. I-Preuves du diagnostic par stimulation auriculaire et ventriculaire. Arch Mal Coeur 1967; 60:1830-1864.
33. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32:695-703.
34. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28:1458-1463.
35. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham Heart Study. Circulation 2003; 107:2920-2925.
36. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32:197-204.
37. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:V194-V101.
38. Savelieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004; 5 (Suppl 1):S5-S19.
39. Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goyal R, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78:1433-1436.
40. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983; 106:284-291.
41. Clark DM, Plumb VJ, Kay GN. The hemodynamics of atrial fibrillation: the independent effect of an irregular RR interval. Circulation 1995; 92(Suppl I):1-141.
42. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and pro-arrhythmic hazards of pharmacologic cardioversion of atrial fibrillation; prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995; 26:852-858.
43. Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Long-term follow up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350:1210-1216.
44. Peters RW, Shorofsky SR, Pelini M, Olsovsky M, Gold MR. Overdrive atrial pacing for reversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J 1999; 137:100-103.
45. Mehra R, Mongeon L. Termination of atrial tachyarrhythmias by pacing techniques. In: Santini M, editor. Progress in clinical pacing. Armonk, New York: Futura Publishing; 1996. pp. 491-502.
46. Chen MS, Marrouche NF, Khaykin Y, Gillinov AM, Wazni O, Martin DO, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004; 43:1004-1009.
47. Haissaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, et al. Catheter ablation of atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351:2373-2383.
48. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111:1100-1105.
49. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
50. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al., for the RACE Investigators. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
51. Hohnloser SH, Kuck KH, Liliental J. Rhythm or rate control in atrial fibrillation-Pharmacologica Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356:1789-1794.
52. Brignole M, Menozzi C, Gasparini M, Bongiorni MG, Botto GL, Ometto R, et al., for the PAF 2 Investigators. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy in patients with paroxysma atrial fibrillation. Eur Heart J 2002; 23:892-900.
53. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al., for the ST AF Investigators. Randomized trial of rate control versus rhythm control in persistent atrial fibrillation: ST AF trial. J Am Coll Cardiol 2003; 41:1690-1696.
54. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2004; 42:1944-1951.
55. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation. A meta analysis. Circulation 2000; 101:1138-1144.
56. Chen RP, Ignaszewski AP, Robertson MA. Successful treatment of supraventricular tachycardia-induced cardiomyopathy with amiodarone: case report and review of literature. Can J Cardiol 1995; 11:918-922.
57. Krapp M, Baschat AA, Gembruch U, Geipel A, Germer U. Flecainide in the treatment of fetal supraventricular tachycardia. Ultrasound Obstet Gynecol 2002; 19:158-164.